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Abstract
Introduction: We previously showed that Link N can stimulate extracellular matrix biosynthesis by intervertebral
disc (IVD) cells, both in vitro and in vivo, and is therefore a potential stimulator of IVD repair. The purpose of the
present study was to determine how Link N may influence human mesenchymal stem cell (MSC) differentiation, as
a prelude to using Link N and MSC supplementation in unison for optimal repair of the degenerated disc.
Methods: MSCs isolated from the bone marrow of three osteoarthritis patients were cultured in chondrogenic or
osteogenic differentiation medium without or with Link N for 21 days. Chondrogenic differentiation was monitored
by proteoglycan staining and quantitation by using Alcian blue, and osteogenic differentiation was monitored by
mineral staining and quantitation by using Alzarin red S. In addition, proteoglycan secretion was monitored with
the sulfated glycosaminoglycan (GAG) content of the culture medium, and changes in gene expression were
analyzed with real-time reverse transcription (RT) PCR.
Results: Link N alone did not promote MSC chondrogenesis. However, after MSCs were supplemented with Link N
in chondrogenic differentiation medium, the quantity of GAG secreted into the culture medium, as well as
aggrecan, COL2A1, and SOX9 gene expression, increased significantly. The gene expression of COL10A1 and
osteocalcin (OC) were downregulated significantly. When MSCs were cultured in osteogenic differentiation
medium, Link N supplementation led to a significant decrease in mineral deposition, and alkaline phosphatase
(ALP), OC, and RUNX2 gene expression.
Conclusions: Link N can enhance chondrogenic differentiation and downregulate hypertrophic and osteogenic
differentiation of human MSCs. Therefore, in principle, Link N could be used to optimize MSC-mediated repair of
the degenerated disc.
Introduction
Intervertebral disc (IVD) degeneration plays a major role
in the etiology of low-back pain (LBP), which can signifi-
cantly affect more than half of the population at some
point during their lives [1-3]. Disc degeneration usually is
associated with increased breakdown of matrix, decreased
synthesis of aggrecan and collagen, cell loss through apop-
tosis, and cluster formation by surviving cells [4-7]. It is
evident that vascular ingrowth can occur into the degener-
ated IVD, and that in painful degenerated IVDs, the ves-
sels are accompanied by nociceptive nerves [1]. Thus,
reversing the degeneration process and repairing the
degenerated IVDs is important for LBP therapy.
Disc repair may be enhanced by cell supplementation to
maximize extracellular matrix production. The source of
cells for disc repair is not immediately apparent, as no
benign site is known for harvesting authentic autologous
disc cells, and it is preferable to avoid the use of allogeneic
donor disc cells. Although the avascular nature of the disc
may make the nucleus pulposus (NP) an immunologically
privileged site, and therefore make the use of allogeneic
cells a tempting proposition, the risk of transferring infec-
tious agents remains real. Thus, we must generate disc
cells from another autologous source.
One possibility is to use mesenchymal stem cells
(MSCs). MSCs are multipotent stem cells that can be iso-
lated, expanded, and stimulated to differentiate into a
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variety of cells, including osteoblasts, chondrocytes, myo-
cytes, adipocytes, and beta pancreatic islets cells [8-11].
Recent studies have shown that MSCs can be used in bio-
logic repair of cartilage or IVD lesions, because of the
bioactive factors secreted by MSCs and the proliferation of
chondrocytes differentiated from MSCs [12-18]. MSCs
can be injected directly, or together with a scaffold, into
the degenerated disc, where they can differentiate into disc
cells, produce extracellular matrix (ECM), and reestablish
healthy disc function [19-22]. It is well known that growth
factors, such as bone morphogenetic proteins (BMPs) and
transforming growth factor-b (TGF-b) can be applied
directly for tissue regeneration. Injecting MSCs together
with growth factors into IVDs can bring added benefits to
the repair process, considering that growth factors and
MSCs can improve tissue repair individually, and growth
factors can stimulate and accelerate the differentiation of
MSCs to chondrocytes.
Hyaline cartilage and healthy NP possess similar macro-
molecules in their extracellular matrix [23-25], although
some differences in the structure of proteoglycans in carti-
lage and the NP have been observed [26]. The production
of an extracellular matrix with a high proteoglycan-to-col-
lagen ratio can distinguish NP cells from chondrocytes
and could help in identifying an NP-like phenotype in
vivo, as opposed to a chondrocyte when MSCs are induced
to differentiate for tissue engineering of a disc [27].
As an economical alternative to growth factors, it may
be possible to use Link N together with MSCs for tissue
regeneration. Link N (DHLSDNYTLDHDRAIH) is the
N-terminal peptide of link protein, a glycoprotein that sta-
bilizes the non-covalent interaction between an aggrecan
G1 domain and hyaluronate. Link N can stimulate the
synthesis of collagen in human articular cartilage and
bovine IVD cells in vitro [28-30], as well as in the IVDs of
rabbits in vivo [31]. Our previous results showed that Link
N can also decrease the expression of type X collagen, a
marker of chondrocyte hypertrophy [32], and stimulate
the expression of type II collagen, a marker of cartilage
and disc ECM [33], in human mesenchymal stem cells
[34]. Thus, Link N has the potential to be used together
with MSCs in promoting the formation of the type of
ECM necessary for IVD repair. However, to be useful for
this purpose, it is essential that Link N does not interfere
with MSC chondrogenesis.
The purpose of this research was to determine the
effects of Link N on human MSCs cultured in chondro-
genic and osteogenic differentiation media to determine
how Link N affects these processes.
Materials and methods
Source and isolation of stem cells
MSCs were obtained from aspirates of the intramedullary
canal of three osteoarthritis patients (aged 40 to 60 years)
undergoing total hip replacement, with a protocol approved
by the Research Ethics Committee of the Jewish General
Hospital (Montreal, QC, Canada). We had all necessary
consent from any patients involved in the study, including
consent to participate in the study and consent to publish.
Bone marrow aspirates were processed as previously
described [34]. In brief, each aspirate was diluted 1:1 (vol/
vol) with Dulbecco Modified Eagle Medium (DMEM) con-
taining 4.5 g/L glucose, L-glutamine, and sodium pyruvate
(Wisent Inc., St-Bruno, QC, Canada) and then layered over
Ficoll (Ficoll-Paque Plus; GE Healthcare Bio-Sciences, Baie-
d’Urfé, QC, Canada). After centrifugation at 900 g for 30
minutes, the mononuclear cell layer was removed from the
interface, washed with DMEM, and resuspended in DMEM
supplemented with 10% fetal bovine serum (FBS; Hyclone,
Logan, UT, USA), 100 units/ml penicillin, and 100 μg/ml
streptomycin. The cells were plated in culture dishes and
incubated at 37°C in a humidified atmosphere with 5%
CO2. After 48 hours, nonadherent cells were washed off,
and the adherent cells were thoroughly washed twice with
DMEM. All cells were expanded in DMEM supplemented
with 10% FBS, 100 units/ml penicillin, 100 μg/ml strepto-
mycin, and were used within four passages.
Cell culture
In every well of a 24-well plate, about 4,000 MSCs were
plated and cultured in expansion medium, high glucose
DMEM with 10% FBS, 100 units/ml penicillin, and 100
μg/ml streptomycin. Floating cells were removed after
allowing MSCs to attach overnight, and then the attached
MSCs were cultured in 1 ml of the same medium for 3
days. The cells were washed with phosphate-buffered sal-
ine (PBS) 3 times, and then were cultured in chondro-
genic or osteogenic differentiation medium. Link N was
dissolved in the differentiation media at a final concentra-
tion of 0.1 μg/ml or 1.0 μg/ml. Differentiation medium
without Link N was used as a control. The medium was
changed every 3 days. The used chondrogenic differentia-
tion media were stored at -20°C for GAG analysis.
For gene expression analysis, 5 × 105 MSCs were pla-
ted on 35 × 10-mm dishes (Sarstedt, Quebec, QC,
Canada). After the cells were cultured in expansion
medium (see earlier) for 3 days, they were cultured in
chondrogenic or osteogenic differentiation medium with
the same conditions as earlier.
To compare the direct effects of Link N and TGF-b3 on
MSC chondrogenesis, MSCs were cultured in serum-free
medium, serum-free medium with 1 μg/ml Link N, or
serum-free medium with 10 ng/ml TGF-b3 for 21 days.
Serum-free medium was prepared with high-glucose
DMEM with 1 × ITS+1 premix (Sigma-Aldrich, Ontario,
QC, Canada), 100 nM dexamethasone, 50 μg/ml ascorbic
acid-2-phosphate, 40 μg/ml proline, 100 units/ml penicil-
lin, and 100 μg/ml streptomycin.
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Chondrogenic differentiation and proteoglycan analysis
Chondrogenic differentiation medium containing TGF-b
was from Invitrogen (Burlington, ON, Canada). Chondro-
genic differentiation was monitored by proteoglycan accu-
mulation by using Alcian blue staining [35]. In brief, after
the cells were cultured for 21 days, the culture medium
was removed, the cells were rinsed gently with PBS twice,
and then fixed with -20°C methanol for 30 minutes. After
rinsing with PBS twice, the wells were stained with Alcian
blue in 0.1N HCl for 30 minutes. The wells were then
rinsed with distilled water 3 times; and images of stained
wells were captured. To quantify proteoglycan, the matrix-
associated dye was extracted with 6 M guanidine-HCl
(Sigma-Aldrich, Oakville, ON, Canada; 200 μl/well) and
measured at 620 nm.
Osteogenic differentiation and mineralization analysis
The osteogenic differentiation medium was prepared with
high-glucose DMEM containing 10% FBS, 0.1 μM dexa-
methasone, 10 mM b-glycerophosphate, 50 μM L-ascorbic
acid, 100 units/ml penicillin, and 100 μg/ml streptomycin.
Osteogenic differentiation was monitored by mineral deposi-
tion by using alizarin red S staining [36]. In brief, after the
cells were cultured for 21 days, the medium was removed,
and the cells were rinsed once with distilled water. The cells
were then fixed with 70% ethanol (stored at -20°C) for
30 minutes. After fixation, the wells were rinsed twice with
distilled water, and the cells were stained with 2% alizarin
red S (pH 4.2) for 30 minutes. Finally, the wells were rinsed
3 times with distilled water, and images of stained wells were
captured. To quantify the matrix mineralization, alizarin red
S was extracted with 100 mM cetylpyridinium chloride
(Sigma-Aldrich; 1 ml/well) and measured at 570 nm.
GAG and DNA analysis
The sulfated glycosaminoglycan (GAG) content of the cul-
ture medium was detected by using a 96-well round-bot-
tom plate [37]. To 20 μl culture medium in every well, 180
μl of 16 mg/L 1,9-dimethylmethylene blue (DMMB;
Sigma-Aldrich) solution was added. The absorbance of the
solution was monitored immediately at 535 nm. Chon-
droitin 6-sulfate from shark cartilage was used as a stan-
dard. DNA was measured on days 3 and 21 by using a
Quant-iT dsDNA High-Sensitivity Assay Kit (Invitrogen,
Burlington, ON, Canada), following the manufacturer’s
instructions. In brief, 20 μl of DNA solution was mixed
with 200 μl of working solution in each well of a 96-well
plate. Fluorescence measurements were taken with an
excitation wavelength of 480 nm and emission wavelength
of 530 nm. A standard curve was obtained from l DNA.
Total RNA isolation
Cells were harvested at days 7, 14, and 21 for gene-expres-
sion studies. Total RNA was extracted from MSCs by
using Trizol (Invitrogen), following the manufacturer’s
instructions. After centrifugation for 15 minutes at
12,000 g at 4°C, the aqueous phase was precipitated with
1 volume of isopropanol, incubated for 45 minutes at -20°
C, and centrifuged again for 15 minutes at 12,000 g at 4°C.
The resulting RNA pellet was washed with 75% ethanol,
centrifuged, and air-dried. The pellets were dissolved in
50 μl diethylpyrocarbonate (DEPC)-treated distilled water
and assayed for RNA concentration, by measuring A260,
and purity, by calculating the A260/A280 ratio.
Reverse transcription
One microgram total RNA isolated from the cells was
digested with DNase I (Invitrogen). Then, 1 μg RNA
was mixed with random primers (final concentration,
0.15 μg/μl), dNTP mixture (final concentration
0.5 mM), and DEPC-treated distilled water to a total
volume of 12 μl. Following the instructions of the
reagent supplier (Invitrogen), the solution was incubated
at 65°C for 5 minutes, and then it was mixed with reac-
tion buffer, DTT, RNaseOUT, and Superscript II reverse
transcriptase with a final volume of 20 μl. The solution
was incubated at 45°C for 50 minutes and then at 70°C
for 15 minutes to inactivate the reverse transcriptase.
Real-time PCR
For LightCycler real-time PCR, a master mix of the follow-
ing reaction components was prepared: 10 μl SYBER PCR
master mix (×1) (Qiagen, Mississauga, ON, Canada), 8 μl
distilled water, 0.5 μl forward primer (0.25 μM), and 0.5 μl
reverse primer (0.25 μM). The nucleotide sequences of the
primers are listed in Table 1. To each 19 μl master mix,
1 μl of cDNA was added as the PCR template. The PCR
conditions included one cycle of initial activation (95°C for
15 minutes, 20°C/s ramp rate), 45 cycles of amplification
and quantification (94°C for 15 seconds, 57°C for
30 seconds, 72°C for 30 seconds), one cycle of melting-
curve determination (65°C to 95°C with heating rate of
0.1°C per second, with a continuous fluorescence measure-
ment), and final cooling to 4°C.
The crossing points (CPs) were determined by the Light-
Cycler software 3.3 (Roche Diagnostics, Indianapolis, IN,
USA) and were measured at constant fluorescence level.
The ratio of gene expression relative to GAPDH as the






Statistical analysis was performed by using analysis of
variance followed by Fisher protected least significant
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difference post hoc test by using Statview (SAS Institute
Inc., Cary, NC, USA). Results are presented as the mean
± standard deviation (SD) of three independent experi-
ments with cells from three different donors. Differences
were considered statistically significant with P < 0.05.
Results
Analysis of MSCs cultured in chondrogenic differentiation
medium with or without Link N demonstrated differentia-
tion into a chondrogenic lineage by Alcian blue staining
(Figure 1A). When Alcian blue was extracted from the
stained cultures (Figure 1B), no significant differences in
proteoglycan deposition were found between control cells
and cells cultured with Link N.
Proteoglycan production during chondrogenic differen-
tiation can also be monitored with GAG analysis, and this
was used to assess the effect of Link N on MSC differentia-
tion. After MSCs were cultured in chondrogenic differen-
tiation medium with Link N for 9, 12, and 15 days, the
quantity of GAG secreted into the culture medium was
significantly higher than that in control medium (Figure 2).
This difference was not observed at days 3, 6, 18, and 21,
although a tendency to increased GAG synthesis with Link
N supplementation was observed on days 6, 18, and 21.
Because the DNA content of the cultures did not change
significantly between days 3 and 21 of culture, the
enhanced GAG synthesis is likely the result of increased
production by each cell rather than a consequence of
having more cells because of cell proliferation.
Aggrecan (ACAN) and COL2A1 are two important genes
that define the chondrocyte phenotype [4,5], and SOX9 is
an important transcription regulator of chondrogenesis
[39,40]. The effect of Link N on the expression of these
genes was therefore assessed. After the cells were cultured
for 7 days in chondrogenic differentiation medium, ACAN
expression with 0.1 μg/ml or 1.0 μg/ml Link N increased
significantly compared with controls (P = 0.001 and 0.002,
respectively) (Figure 3A). The increase was also observed
after 14 days (P = 0.003 for 0.1 μg/ml Link N; P = 0.004 for
1.0 μg/ml Link N). Similarly, COL2A1 expression was also
increased compared with control cells at both day 7 (P =
0.003 for 0.1 μg/ml Link N; P = 0.005 for 1.0 μg/ml Link N)
and day 14 (P = 0.003 for 0.1 μg/ml Link N, P = 0.002 for
1.0 μg/ml Link N) (Figure 3B). Compared with control
cells, the expression of SOX9 was increased at day 7 (P =
0.017 for 0.1 μg/ml Link N; P = 0.027 for 1.0 μg/ml Link N)
and day 14 (P = 0.024 for 0.1 μg/ml Link N; P = 0.011 for
Table 1 Primer sequences
Gene Sequence Size
ACAN Forward (6708-6727): TGA GTC CTC AAG CCT CCT GT 185
bp
Reverse (6873-6892): CCT CTG TCT CCT TGC AGG TC
ALP Forward (1397-1416): CCA CGT CTT CAC ATT TGG TG 196
bp
Reverse(1573-1592): AGA CTG CGC CTG GTA GTT GT




Reverse (1779-1799): ACA AGT AAA GAT TCC AGT
CCT
COL2A1 Forward (459-478): ATT TCA AGG CAA TCC TGG TG 218
bp
Reverse (657-676): GGC CTG GAT AAC CTC TGT GA




Reverse (273-293): TTC TCA GCC TTG ACG GTG CCA
OC Forward (20-39): TGA GAG CCC TCA CAC TCC TC 151
bp
Reverse (170-151): CGC CTG GGT CTC TTC ACT AC




Reverse (1470-1489): CAG CGT CAA CAC CAT CAT TC
SOX9 Forward (19-38): TTC ATG AAG ATG ACC GAC GA 175
bp
Reverse (174-193): CGC TCT CCT TCT TCA GAT CG
Figure 1 Effect of Link N on proteoglycan deposition by
mesenchymal stem cells (MSCs) in chondrogenic differentiation
medium. (A) Alcian blue staining of proteoglycan in extracellular
matrix after MSCs were cultured in chondrogenic differentiation
medium without (control) or with Link N for 21 days. (B) The
absorbance value of the solubilized Alcian blue at 620 nm. The
results are shown as mean ± SD of three independent experiments
with MSCs from three different donors.
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>Figure 2 Glycosaminoglycan (GAG) secretion into 1-ml culture medium over the 3-day period preceding medium collection when
mesenchymal stem cells (MSCs) were cultured in chondrogenic differentiation medium in the absence (control) or presence of Link N.
The results are shown as mean ± SD of three independent experiments with MSCs from three different donors. *P < 0.05 versus control.
>Figure 3 Relative ratio of ACAN (A), COL2A1 (B), and SOX9 (C) gene expression in mesenchymal stem cells (MSCs) cultured in
chondrogenic differentiation medium without (control) or with 0.1 or 1.0 μg/ml Link N for 7, 14, and 21 days. The results are shown as
mean ± SD of three independent experiments with MSCs from three different donors. *P < 0.05 versus control.
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1.0 μg/ml Link N) (Figure 3C). For the expression of all
three genes, no significant difference was observed between
the two concentrations of Link N. Thus Link N appeared
to promote the chondrogenic differentiation of MSCs.
COL10A1 is a marker gene for hypertrophic chondro-
cyte differentiation, a process that is undesirable for effec-
tive disc or cartilage repair [41,42]. When MSCs were
cultured in chondrogenic differentiation medium with
1.0 μg/ml Link N for 7 (P = 0.002), 14 (P = 0.001) and
21 days (P = 0.007), gene expression was downregulated
significantly (Figure 4A). When MSCs were cultured in
chondrogenic differentiation medium with 0.1 μg/ml Link
N for 7 and 14 days, no significant difference of COL10A1
expression was observed compared with the control cells.
However, a significant difference was observed at day 21
(P = 0.015). The difference between cells cultured in
different concentrations of Link N was significant at day 7
(P = 0.006). Thus, Link N appears to reduce hypertrophic
differentiation by the MSCs.
Because another major problem with MSC-based
chondrogenesis is their osteogenic differentiation, we
next explored the effect of Link N on osteocalcin (OC),
an important osteogenic marker [43,44]. When MSCs
were cultured in chondrogenic differentiation medium
with 0.1 μg/ml and 1.0 μg/ml Link N for 21 days, the
expression of OC was significantly downregulated
(P < 0.001) (Figure 4B).
To determine whether Link N can directly stimulate
chondrogenesis, MSCs were cultured in serum-free
medium without (control) or with either Link N or TGF-
b3. Proteoglycan deposition in the accumulated ECM was
visualized by staining with Alcian blue (Figure 5A). When
Alcian blue was extracted from the stained cultures, only
TGF-b3 supplementation led to increased proteoglycan
deposition when compared with the control cells and
those cultured with Link N (Figure 5B). Thus, Link N
alone does not directly stimulate chondrogenesis in a
manner analogous to TGF-b, but rather enhances ongoing
chondrogenesis.
After MSCs were cultured in osteogenic differentiation
medium without or with 0.1 or 1.0 μg/ml Link N for 21
days, mineral deposition in the accumulated ECM was
visualized by staining with alizarin red S (Figure 6A).
With the higher concentration of Link N, a decrease
appeared to exist in the extent of matrix mineralization.
When alizarin red S was extracted from the matrix,
mineral deposition in the presence of 1.0 μg/ml Link N
was shown to be decreased significantly compared with
control cells (Figure 6B).
Alkaline phosphatase (ALP) and osteocalcin (OC) are
important genes to define the osteogenic phenotype
[43-45], and RUNX2 is an important transcription regulator
of osteogenesis [45,46]. The effect of Link N on the expres-
sion of these genes was therefore assessed. After the cells
were cultured in osteogenic differentiation medium with 1.0
μg/ml Link N for 7 days, ALP (P = 0.017), OC (P = 0.016),
and RUNX2 (P = 0.019) expression decreased significantly
compared with that in control cells (Figure 7A through C).
Figure 4 Relative ratio of COL10A1 (A) and OC (B) gene expression in mesenchymal stem cells (MSCs) cultured in chondrogenic
differentiation medium without (control) or with 0.1 or 1.0 μg/ml Link N. The expression of COL10A1 was detected after the cells were
cultured for 7, 14, or 21 days. The expression of OC was detected after the cells were cultured for 21 days. The results are shown as mean ± SD
of three independent experiments with MSCs from three different donors. *P < 0.05 versus control.
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No obvious effect was detected with 0.1 μg/ml Link N. At
day 21, no significant difference of ALP, OC, and RUNX2
expression was observed compared with control cells for
either 0.1 or 1.0 μg/ml Link N. Thus, at the higher concen-
tration, Link N appeared to downregulate the osteogenic
differentiation potential of the MSCs.
Discussion
If Link N is to be used to stimulate disc repair in the pre-
sence of MSCs, it is essential that it does not interfere with
chondrogenic differentiation and, ideally, promotes it. The
results of the present work indicate that Link N can induce
the expression of aggrecan and type II collagen, possibly
through activation of SOX9 expression, and that the upre-
gulation of aggrecan gene expression can increase proteo-
glycan production. Aggrecan and type II collagen are two
important components of the extracellular matrix in IVD,
and their degradation is associated with IVD degeneration
[4,5,47]. Restoration of aggrecan and type II collagen levels
within the disc ECM is therefore an essential requisite for
disc repair. Thus Link N has the potential to be used
together with MSCs in repairing degenerated IVDs.
It should be noted that although in vitro chondrogenesis
is performed mostly in either pellet cultures or in a 3D
environment, such as a hydrogel, the experiments pre-
sented here were not performed under these conditions.
Monolayer culture was preferred, as it better mimics how
stem cells will deposit on the disc ECM if they are to be
injected in vivo for biologic repair. Future studies will be
conducted to determine whether injection of Link N
together with MSCs in an animal model of disc degenera-
tion or into degenerated human discs in organ culture can
promote ECM production.
A key consideration in using MSCs for repairing degen-
erated IVDs is not only the promotion of chondrogenesis,
but also the prevention of hypertrophy and osteogenesis
[48,49]. In the present work, such a process is indicated by
decreased gene expression of type X collagen, a marker for
hypertrophy, as well as ALP and OC, two important bone-
matrix proteins synthesized by osteoblasts, and by
Figure 5 Effect of Link N on proteoglycan deposition by
mesenchymal stem cells (MSCs) in serum-free medium. (A)
Alcian blue staining of proteoglycan in extracellular matrix after
MSCs were cultured in serum-free medium devoid of TGF-b
(control), serum-free medium with 1 μg/ml Link N, and serum-free
medium with 10 ng/ml TGF-b3 for 21 days. (B) The absorbance
value of the solubilized Alcian blue at 620 nm. The results are
shown as mean ± SD of three independent experiments with MSCs
from three different donors.
Figure 6 Effect of Link N on mineral deposition by
mesenchymal stem cells (MSCs) in osteogenic differentiation
medium. (A) Alizarin red staining of mineral deposition in the
extracellular matrix after MSCs were cultured in osteogenic
differentiation medium without (control) or with Link N for 21 days.
(B) The absorbance value of solubilized alizarin red measured at 620
nm. The results are shown as mean ± SD of three independent
experiments with MSCs from three different donors. *P < 0.05
versus control.
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decreased matrix mineralization through calcium deposi-
tion [50]. The ability of Link N to decrease the expression
of ALP and OC may be through downregulating the tran-
scription regulator RUNX2. Thus Link N can both favor
chondrogenic differentiation of MSCs and retard their
hypertrophic and osteogenic differentiation.
In the present study, it was not our intention to address
directly the ability of Link N to promote chondrogenic,
osteogenic, or disc-like differentiation. The goal of the work
was to check that Link N does not negatively interfere with
chondrogenesis, a differentiation pathway common to disc
cells, which make matrix molecules common to all carti-
lages. Stem cell conversion to an NP-like phenotype rather
than a hyaline cartilage is distinguished by the production
of a gelatinous matrix with a proteoglycan-to-collagen ratio
of approximately 28:1 [27]. When Link N is used in vivo, it
is expected that growth factors such as TGF-b will always
be present, and that these, coupled with the unique extra-
cellular milieu, will guide the formation of either a disc-like
or a cartilage-like matrix.
The influences of Link N on stimulating chondrogen-
esis and decreasing osteogenesis are similar to those
reported with BMP and TGF-b [51,52]. However, one
major advantage of Link N over a growth factor such as
TGF-b for therapeutic use is the large saving in cost.
For example, Link N costs $750 for 50 mg of the
Figure 7 The relative ratio of ALP (A), OC (B), and RUNX2 (C) gene expression in mesenchymal stem cells (MSCs) cultured in
osteogenic differentiation medium without (control) or with 0.1 or 1.0 μg/ml Link N for 7 and 21 days. The results are shown as mean
± SD of three independent experiments with MSCs from three different donors. *P < 0.05 versus control.
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synthetic peptide, which is about 2 cents per microgram
for supplementation. In contrast, TGF-b3 costs $30 per
microgram. Link N therefore represents an economic
therapeutic agent with potentially beneficial effects on
disc repair when used either alone or in the presence of
MSCs.
Previous studies have shown that Link N can stimulate
the synthesis of proteoglycans and collagens in both articu-
lar cartilage and IVD [28-30]. The present data indicate
that Link N and MSCs can synergize to stimulate chondro-
genesis while suppressing osteogenesis. These are features
needed not only for any agent designed to stimulate disc
repair but also for any agent designed to stimulate articular
cartilage repair. Therefore, in principle, disc and cartilage
repair may be enhanced by stem cell supplementation in
the presence of Link N to maximize extracellular matrix
production. Such a beneficial effect does, however, assume
that there is no nutrient deprivation that could impair cell
metabolism. Although this could be a potential impediment
to disc repair because of its avascular nature and the lack of
a bathing nutrient fluid, it is less likely to be a detriment to
articular cartilage repair where the tissue is bathed in syno-
vial fluid and nutrient-diffusion distances are relatively
short. Only future in vivo studies will be able to determine
whether biologic repair of the degenerate disc by Link N
and MSC supplementation could be a reality.
The present data indicate that Link N alone cannot
directly promote MSC chondrogenesis. Thus, together
with the other data, it appears that Link N enhances
ongoing chondrogenesis rather than initiates it. Further-
more, Link N appears to be capable of reducing hyper-
trophic differentiation of chondrocytes. These results
have implications in relation to regenerating a functional
nucleus pulposus in the degenerated IVD or in repairing
cartilage.
Conclusions
In addition to promoting chondrogenesis and stimulat-
ing the gene expression of aggrecan and type II collagen,
Link N also is able to downregulate osteogenesis and the
gene expression oftype X collagen, alkaline phosphatase,
and osteocalcin. Interestingly, these properties of Link N
are similar to those reported previously for several
growth factors and are features needed for any biologic
agent designed to stimulate disc or cartilage repair.
Therefore, in principle, Link N and MSC supplementa-
tion could have therapeutic value for the treatment of
degenerative lesions in both disc and articular cartilage.
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